| 主要作者 | 摘要标题 | 演示文稿详情 (CDT) |
| 抗体偶联药物 |
| Shitara, K | Trastuzumab deruxtecan (T-
DXd) vs ramucirumab (RAM) +
paclitaxel (PTX) in second-line
treatment of patients (pts) with
human epidermal growth factor
receptor 2-positive (HER2+)
unresectable/metastatic gastric
cancer (GC) or
gastroesophageal junction
adenocarcinoma (GEJA):
Primary analysis of the
randomized, phase 3
DESTINY-Gastric04 study. | Abstract #LBA4002 Oral Abstract Session 31 May 2025 3:24pm |
| Tolaney, SM | Trastuzumab deruxtecan (T-
DXd) + pertuzumab (P) vs
taxane + trastuzumab +
pertuzumab (THP) for first-line
(1L) treatment of patients (pts)
with human epidermal growth
factor receptor 2–positive
(HER2+) advanced/metastatic
breast cancer (a/mBC): Interim
results from DESTINY-Breast09. | Abstract #LBA1008 Oral Abstract Session 2 June 2025 7:30am |
| Dent, R | Exploratory biomarker analysis
of trastuzumab deruxtecan (T-
DXd) vs physician's choice of
chemotherapy (TPC) in HER2-
low/-ultralow, hormone
receptor-positive (HR+)
metastatic breast cancer (mBC)
in DESTINY-Breast06 (DB-06). | Abstract #1013 Oral Abstract Session 31 May 2025 3:23pm |
| Levy, BP | TROPION-Lung02:
Datopotamab deruxtecan
(Dato-DXd) plus
pembrolizumab (pembro) with
or without platinum
chemotherapy (Pt-CT) as first-
line (1L) therapy for advanced
non-small cell lung cancer (aNSCLC). | Abstract #8501 Oral Abstract Session 1 June 2025 8:12am |
| Waqar, SN | First-line (1L) datopotamab
deruxtecan (Dato-DXd) +
rilvegostomig in advanced or
metastatic non-small cell lung
cancer (a/mNSCLC): Results
from TROPION-Lung04 (cohort 5). | Abstract #8521 Poster Session 31 May 2025 1:30pm |
| 肿瘤驱动因素和耐药性 |
| Turner, NC | Camizestrant + CDK4/6
inhibitor (CDK4/6i) for the
treatment of emergent ESR1
mutations during first-line (1L)
endocrine-based therapy (ET)
and ahead of disease
progression in patients (pts)
with HR+/HER2– advanced
breast cancer (ABC): Phase 3,
double-blind ctDNA-guided
SERENA-6 trial. | Abstract #LBA4 Plenary Session 1 June 2025 2:41pm |
| Lu, S | Savolitinib (Savo) combined
with osimertinib (osi) versus
chemotherapy (chemo) in
EGFR-mutant (EGFRm) and
MET-amplification (METamp)
advanced NSCLC after disease
progression (PD) on EGFR
tyrosine kinase inhibitor (TKI):
Results from a randomized
phase 3 SACHI study. | Abstract #LBA8505 Oral Abstract Session 1 June 2025 9:48am |
| Levy, BP | Efficacy and CNS results from
a randomized subset of the
phase 2 SAVANNAH study
comparing savolitinib (savo) +
osimertinib (osi) combination
with savo + placebo (PBO). | Abstract #8513 Rapid Oral Abstract Session 2 June 2025 8:06am |
| Chaft JE | Neoadjuvant (neoadj)
osimertinib (osi) ±
chemotherapy (CT) vs CT
alone in resectable (R)
epidermal growth factor
receptor-mutated (EGFRm)
NSCLC: NeoADAURA. | Abstract #8001 Oral Abstract Session 2 June 2025 3:12pm |
| 免疫肿瘤学与双特异性抗体 |
| Janjigian, YY | Event-free survival in
MATTERHORN: a randomized,
phase 3 study of durvalumab
plus 5-fluorouracil, leucovorin,
oxaliplatin, and docetaxel
chemotherapy (FLOT) in
resectable
gastric/gastroesophageal
junction cancer (GC/GEJC). | Abstract #LBA5 Plenary Session 1 June 2025 3:13pm |
| Powles, T | Circulating tumor DNA (ctDNA)
in patients with muscle-invasive
bladder cancer (MIBC) who
received perioperative
durvalumab (D) in NIAGARA | Abstract #4503 Oral Abstract Session 1 June 2025 10:45am |
| Reck, M | Associations of post-surgical
MRD status with neoadjuvant
ctDNA dynamics, genomic
mutations, and clinical
outcomes in patients with
resectable NSCLC (R-NSCLC)
from the phase 3 AEGEAN trial. | Abstract #8009 Rapid Oral Abstract Session 1 June 2025 4:30pm |
| Barbie, DA | Clinical and molecular
characteristics of early
progressors (EPs) and long
-term progression-free survivors
(LTPs) from the phase 3
ADRIATIC trial of
consolidation durvalumab (D) vs placebo (P)
after concurrent
chemoradiotherapy (cCRT) in
limited-stage small-cell lung
cancer (LS-SCLC). | Abstract #8014 Rapid Oral Abstract Session 1 June 2025 5:12pm |
| Mayadev, J | Ultrasensitive detection and
tracking of circulating tumor
DNA (ctDNA) and association
with relapse and survival in
locally advanced cervical
cancer (LACC): Phase 3
CALLA trial analyses. | Abstract #5502 Oral Abstract Session 2 June 2025 8:48am |
| Westin, SN | Durvalumab plus
carboplatin/paclitaxel followed
by durvalumab with or without
olaparib as first-line treatment
for endometrial cancer:
Longitudinal changes in
circulating tumor DNA. | Abstract #5512 Rapid Oral Abstract Session 3 June 2025 8:30am |
| Erinjeri, JP | Outcomes by baseline tumor
burden using the 6-and-12
score in EMERALD-1: a phase
3 study of durvalumab (D) ±
bevacizumab (B) with transarterial
chemoembolization (TACE) in
embolization-eligible
unresectable hepatocellular
carcinoma (uHCC). | Abstract #4083
Poster Session 31 May 2025 9:00am |
| Cascone, T | Neoadjuvant durvalumab (D) +
chemotherapy (CT) + novel
anticancer agents and adjuvant
D ± novel agents in resectable
non-small-cell lung cancer
(NSCLC): Updated outcomes
from NeoCOAST-2. | Abstract #8046 Poster Session 31 May 2025 1:30pm |
| Zhou, J | First-line rilvegostomig (rilve)
plus chemotherapy (CTx) in
advanced biliary tract cancer
(BTC): Primary analysis of
GEMINI-Hepatobiliary substudy
2 Cohort A. | Abstract #4080 Poster Session 31 May 2025 9:00am |
| Xu, R | ARTEMIDE-Gastric01: a phase
3 randomized study of
rilvegostomig with
fluoropyrimidine and
trastuzumab deruxtecan (T-
DXd) as first-line (1L) treatment
for locally advanced or
metastatic HER2-positive
gastric or gastroesophageal
junction cancer (GC/GEJC). | Abstract #TPS4204 Poster Session 31 May 2025 9:00am |
| Mathias, C | ARTEMIDE-Lung03: a phase 3,
randomized, double-blind,
multicenter, global study of
rilvegostomig or
pembrolizumab in combination
with platinum-based
chemotherapy as first-line
treatment for patients with
metastatic non-squamous non-
small-cell lung cancer whose
tumors express PD-L1. | Abstract #TPS8653 Poster Session 31 May 2025 1:30pm |
| 细胞疗法 |
| Yoo, C | RHEA-1: First-in-human (FIH)
study of AZD9793, a first-in-
class CD8-guided T cell-
engager (TCE) for glypican-3-
positive (GPC3+) advanced or
metastatic hepatocellular
carcinoma (HCC). | Abstract #TPS4215 Poster Session 31 May 2025 9:00am |
| Kim, TM | Safety and Efficacy of
AZD0486, a CD19xCD3 T-cell
Engager, in Relapsed or
Refractory Diffuse Large B-cell
Lymphoma. | Abstract #7046
Poster Session 1 June 2025 9:00am |
| Shadman, M | TITANium: An open-label,
global multicenter Phase 1/2
study of AZD5492, a first-in-
class subcutaneous CD8-
guided tri-specific T-cell
engager (TCE), in patients (pts)
with relapsed or refractory (r/r)
B-cell malignancies. | Abstract #TPS7091 Poster Session 1 June 2025 9:00am |
| Le Gouill, S | SOUNDTRACK-E: A Phase 1/2
Open-label Multicenter Study to
Evaluate the Safety and
Efficacy of AZD0486
Monotherapy or Combination
Therapy in Patients With
Mature B-cell Malignancies. | Abstract #TPS7083 Poster Session 1 June 2025 9:00am |
| 罕见病药物 |
| Chen, AP | Efficacy and safety of
selumetinib in adults with
neurofibromatosis type 1 (NF1)
and symptomatic, inoperable
plexiform neurofibroma (PN):
Primary analysis of KOMET
(NCT04924608), a Phase 3,
international, randomized,
placebo-controlled study. | Abstract #3014 Rapid Oral Abstract Session 2 June 2025 8:00am |
